Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
san diego blog main
5
×
san diego top stories
startups
5
×
new york blog main
boston blog main
clinical trials
deals
fda
ipo
melinta therapeutics
national top stories
new york top stories
san francisco blog main
san francisco top stories
vc
biogen
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
financing
gilead sciences
indiana blog main
indiana top stories
national
novartis
raleigh-durham blog main
raleigh-durham top stories
rna
san diego
seattle blog main
seattle top stories
What
medicines
5
×
new
bio
covid
deal
diseases
ipo
roundup
acquisitions
activity
advance
aiming
ambys
announced
approvals
bacteria
big
biogen
biologics
biopharma
biotech
business
ceo
clamped
collabs
company
considered
control
daniel
deadly
debuted
delays
deliver
developing
disease
drug
drugs
dtx
economic
exited
Language
unset
Current search:
startups
×
medicines
×
" san diego blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
